Sai Life Sciences, a leading global contract research, development, and manufacturing organization (CRDMO), recently convened its highly anticipated Biotech Pitch…
Read More
Biogen Secures Global Rights to TJ Biopharma’s Felzartamab in Landmark $850 Million Deal, Aiming to Disrupt Multiple Myeloma Treatment Landscape
Biogen announced on April 20, 2026, a significant strategic acquisition, securing exclusive rights to TJ Biopharma’s novel anti-CD38 immunotherapy, felzartamab,…
Read More
McGill University Researchers Identify Specific Brain Cells Linked to Depression in Landmark Study
A groundbreaking study led by researchers at McGill University and the Douglas Research Centre has fundamentally altered the scientific understanding…
Read More
Innovative Gene Therapy Targets Chronic Pain Circuits Without Addiction Risk in Landmark Preclinical Study
In a significant advancement for neurobiology and pain management, researchers from the University of Pennsylvania, Stanford University, and Carnegie Mellon…
Read More
Glucose Revealed as Master Regulator of Tissue Differentiation in Landmark Stanford Medicine Study
In a discovery that fundamentally alters the scientific understanding of cellular metabolism, researchers at Stanford Medicine have identified that glucose,…
Read More
Unprecedented Growth Rates and Early Genetic Origins of Chronic Myeloid Leukemia Revealed in Landmark Genomic Study
A comprehensive genomic study published in the journal Nature has fundamentally altered the scientific understanding of chronic myeloid leukemia (CML),…
Read More
Kailera Therapeutics Secures $625 Million in Landmark IPO to Accelerate Obesity Drug Development
Obesity-focused biotechnology firm Kailera Therapeutics has successfully launched its Initial Public Offering (IPO), raising an impressive $625 million. This significant…
Read More
Novo Nordisk Forges Landmark AI Partnership with OpenAI to Revolutionize Drug Development Amidst Intensifying Competition
The pharmaceutical industry is witnessing an unprecedented surge in artificial intelligence (AI) adoption, with Novo Nordisk, a global leader in…
Read More
Filspari Secures Landmark FDA Approval for Focal Segmental Glomerulosclerosis (FSGS) in Adults and Pediatric Patients Aged Eight and Above
Travere Therapeutics has achieved a significant milestone in the treatment of rare kidney diseases with the U.S. Food and Drug…
Read More
UCSF Researchers Identify FTL1 Protein as Primary Driver of Hippocampal Aging and Memory Loss in Landmark Study
The aging process exerts a profound and often debilitating toll on the hippocampus, the specialized region of the brain fundamentally…
Read More
